SubHero Banner

Olumiant® (baricitinib) – New drug approval

June 1, 2018 - Eli Lilly and Incyte announced the FDA approval of Olumiant (baricitinib), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Download PDF